|
AU2007231727A1
|
|
Water stabilized medicinal aerosol formulation
|
|
WO2008100249A1
|
|
Low flush niacin formulation
|
|
WO2007149119A1
|
|
Water stabilized aerosol formulation system and method of making
|
|
CA2569776A1
|
|
Low flush niacin formulation
|
|
KR20080030563A
|
|
Dose counter for metered dose inhalers
|
|
US2006289006A1
|
|
Breath actuated nasal drug delivery system
|
|
US2006243275A1
|
|
Breath actuated inhaler
|
|
WO2005009325A2
|
|
Apparatus for electronic dosage counter
|
|
AU2004233805A1
|
|
Formation of strong superporous hydrogels
|
|
MXPA05002337A
|
|
Water stabilized medicinal aerosol formulation related applications.
|
|
AU2002300546B2
|
|
Combinations of HMG-CoA Reductase Inhibitors and Nicotinic Acid and Methods for Treating Hyperlipidemia
|
|
AU4751802A
|
|
Starter kit containing nicotinic acid compositions
|
|
MXPA03009661A
|
|
A release pharmaceutical construct for gastric retention.
|
|
CA2453782A1
|
|
Core formulation comprising troglitazone and a biguanide
|
|
MXPA04000180A
|
|
Core formulation comprising pioglitazone hydrochloride and a biguanide.
|
|
AU2001273310B2
|
|
A core formulation
|
|
AU2001251737B2
|
|
Method for measuring changes in the airways of humans and other mammals
|
|
NZ525486A
|
|
Combination of HMG-COA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
|
|
NZ520176A
|
|
Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
|
|
CA2574987A1
|
|
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
